Mosby's 2014 Nursing Drug Reference (172 page)

BOOK: Mosby's 2014 Nursing Drug Reference
5.26Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

fenofibrate (Rx)

(fen-oh-fee′brate)

Antara, Apo-Feno-Micro
, Fenoglide, Lipidil Micro
, Lipidil Supra Cap, Lipofen, Lofibra, Tricor, Triglide

Func. class.:
Antilipemic

Chem. class.:
Fibric acid derivative

ACTION:

Increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase, thereby resulting in changes in triglyceride size and composition of LDL, leading to rapid breakdown of LDL; mobilizes triglycerides from tissue; increases excretion of neutral sterols

USES:

Hypercholesterolemia; types IV, V hyperlipidemia that do not respond to other treatment and that increase risk for pancreatitis; Fredrickson type IV, V hypertriglyceridemia

CONTRAINDICATIONS:

Hypertensivity, severe renal/hepatic disease, primary biliary cirrhosis, preexisting gallbladder disease

Precautions:
Pregnancy (C), breastfeeding, geriatric patients, peptic ulcer, pancreatitis, renal/hepatic disease

DOSAGE AND ROUTES
Calculator
Hypertriglyceridemia

• Adult:
PO
(Antara) 43-130 mg/day; (Lofibra) 67-200 mg/day; (Tricor) 48-145 mg/day; (Triglide) 50-160 mg/day

Primary hypercholesterolemia/mixed hyperlipidemia

• Adult:
PO
(Antara) 130 mg/day; (Lofibra) 200 mg/day; (Tricor) 145 mg/day; (Triglide) 160 mg/day

Renal dose (geriatric)

• Adult:
PO
(Tricor) CCr 30-80 ml/min, 48 mg/day; CCr <30 ml/min, contraindicated

• Adult:
PO
CCr 30-48 ml/min, 50 mg/day (Triglide, Liprofen), 43 mg/day (Antara), 67 mg/day (Lofibra caps), 54 mg/day (Lofibra tabs); CCr <10 ml/min, contraindicated (Antara, Lipofen, Lofibra, Triglide); 40 mg/day (Fenoglide)

Available forms:
Tabs (Triglide) 50, 160 mg; (Tricor) 48, 145 mg; micronized cap (Antara) 43, 130 mg; (Lofibra) 67, 134, 200 mg; cap (Lipofen) 50, 100, 150 mg; tabs (Fenoglide) 40, 120 mg

Administer:

• 
Product with meals (Lipofen, Lofibra); Triglide without regard to food; may increase q4-8wk; brands are not interchangeable; therapy should be discontinued if there is not adequate response after 2 mo

SIDE EFFECTS

CNS:
Fatigue, weakness
, drowsiness, dizziness, insomnia, depression, vertigo

CV:
Angina, hypertension

GI:
Nausea
, vomiting, dyspepsia, increased liver enzymes, flatulence, hepatomegaly, gastritis,
pancreatitis, cholelithiasis

GU:
Dysuria, urinary frequency

HEMA:
Anemia, leukopenia,
thrombosis/pulmonary embolism

INTEG:
Rash
, urticaria, pruritus, photosensitivity

MISC:
Polyphagia, weight gain, infection, flulike syndrome

MS:
Myalgias, arthralgias
,
myopathy, rhabdomyolysis

RESP:
Pharyngitis, bronchitis, cough

PHARMACOKINETICS

Peak 6-8 hr, protein binding 99%, converted to fenofibric acid, metabolized in liver, excreted in urine (60%), feces (25%), half-life 20 hr

INTERACTIONS

Increase:
myopathy—colchicine

Increase:
nephrotoxicity—cycloSPORINE

• 
Avoid use with HMG-CoA reductase inhibitors; rhabdomyolysis may occur

Increase:
anticoagulant effects—oral anticoagulants

Increase:
effects of—antidiabetics

Decrease:
absorption of fenofibrate—bile acid sequestrants

Drug/Herb

Increase:
effect—red yeast rice

Drug/Food

Increase:
absorption

Drug/Lab Test

Increase:
ALT, AST, BUN, CK, creatinine

Decrease:
WBC, uric acid, Hgb, paradoxical effect in HDL

NURSING CONSIDERATIONS
Assess:

• 
Diet history:
fat content; lipid levels (triglycerides, LDL, HDL, cholesterol), may cause a paradoxical decrease in HDL, LFTs at baseline, periodically during treatment, CPK if muscle pain occurs, CBC, Hct, Hgb; PT with anticoagulant therapy

• 
Pancreatitis, cholelithiasis renal failure, rhabdomyolysis
(when combined with HMG Co-A reductase inhibitors), myositis; product should be discontinued

Evaluate:

• 
Therapeutic response: decreased triglycerides, cholesterol levels

Teach patient/family:

• 
That compliance is needed

• 
That risk factors should be decreased: high-fat diet, smoking, alcohol consumption, absence of exercise

• 
To notify prescriber if pregnancy is suspected or planned

• 
To report GU symptoms: decreased libido, impotence, dysuria, proteinuria, oliguria, hematuria

• 
To notify prescriber of muscle pain, weakness, fever, fatigue, epigastric pain

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

HIGH ALERT
fentaNYL (Rx)

(fen′ta-nill)

ABSTRAL, Actiq, Fentora, Onsolis, RAN-Fentanyl

fentaNYL transdermal (Rx)

Duragesic

fentaNYL nasal spray (Rx)

Lazanda

fentaNYL SL spray

Subsys

Func. class.:
Opioid analgesic

Chem. class.:
Synthetic phenylpiperidine

Other books

Bluebells on the Hill by Barbara McMahon
Only with You by Lauren Layne
Después del silencio by Charlotte Link
The Alpha's Reluctant Mate by Williams, Morganna
Amy's Advantage by Eve Jameson
Royal Regard by Mariana Gabrielle